Published in Blood on September 27, 2007
Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive (DART4MM) | NCT03992170
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol (2008) 3.21
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia (2013) 3.08
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood (2010) 2.12
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia (2009) 1.97
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant (2013) 1.88
Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol (2009) 1.88
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell (2009) 1.73
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist (2013) 1.70
A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood (2014) 1.61
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood (2014) 1.56
Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. Biol Blood Marrow Transplant (2014) 1.55
Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist (2011) 1.45
Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. Haematologica (2011) 1.43
Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica (2009) 1.39
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica (2009) 1.38
European perspective on multiple myeloma treatment strategies in 2014. Oncologist (2014) 1.28
Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia (2013) 1.21
Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia (2014) 1.20
Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States. J Clin Oncol (2013) 1.19
Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement. Scientifica (Cairo) (2013) 1.15
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia (2010) 1.14
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood (2011) 1.13
Smoldering multiple myeloma requiring treatment: time for a new definition? Blood (2013) 1.09
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood (2012) 1.08
Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol (2009) 1.07
The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J (2011) 1.07
Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant (2012) 1.06
The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. J Hematol Oncol (2010) 1.05
Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist (2010) 1.04
Therapeutic advancements in multiple myeloma. Front Oncol (2014) 0.96
Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol (2013) 0.96
Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol (2014) 0.95
Cytotoxicity of graphene oxide and graphene oxide loaded with doxorubicin on human multiple myeloma cells. Int J Nanomedicine (2014) 0.95
Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant (2014) 0.93
Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica (2012) 0.92
Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. J Biomed Opt (2011) 0.92
Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant (2014) 0.91
Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J (2015) 0.91
Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica (2014) 0.89
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica (2015) 0.89
Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma. Bone Marrow Transplant (2013) 0.88
The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Ther Adv Hematol (2014) 0.88
The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica (2012) 0.88
Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia (2013) 0.88
Changing paradigms in the treatment of multiple myeloma. Haematologica (2009) 0.87
Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Cancer (2013) 0.87
Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center. Bone Marrow Transplant (2012) 0.86
Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood (2015) 0.86
Diagnosis and therapy of multiple myeloma. Korean J Intern Med (2013) 0.84
Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica (2011) 0.84
Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients. Exp Ther Med (2013) 0.84
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica (2015) 0.83
Multiple myeloma in the very old: an IASIA conference report. J Natl Cancer Inst (2014) 0.83
Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells. Clin Lymphoma Myeloma Leuk (2015) 0.83
Multiple Myeloma, Version 2.2016. J Natl Compr Canc Netw (2015) 0.81
Pursuing the curative blueprint for early myeloma. Blood (2013) 0.81
Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents. Bone Marrow Transplant (2014) 0.81
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. Clin Cancer Res (2013) 0.81
Trends in the incidence and survival of multiple myeloma in South East England 1985-2004. BMC Cancer (2010) 0.81
Quality of life and supportive care in multiple myeloma. Turk J Haematol (2013) 0.80
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Am J Hematol (2010) 0.79
Early mortality in multiple myeloma. Leukemia (2015) 0.79
Survival from multiple myeloma in England and Wales up to 2001. Br J Cancer (2008) 0.79
New Treatment Approaches for Older Adults with Multiple Myeloma. J Geriatr Oncol (2012) 0.79
The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis (2010) 0.78
Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies. J Exp Clin Cancer Res (2015) 0.78
Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece. Cancer Manag Res (2013) 0.78
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res (2015) 0.78
Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma. Am J Hematol (2014) 0.78
Are ongoing trials on hematologic malignancies still excluding older subjects? Haematologica (2013) 0.78
Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J (2015) 0.78
Decursin and Doxorubicin Are in Synergy for the Induction of Apoptosis via STAT3 and/or mTOR Pathways in Human Multiple Myeloma Cells. Evid Based Complement Alternat Med (2013) 0.77
Immunotherapeutic approaches to treat multiple myeloma. Hum Vaccin Immunother (2013) 0.77
Future distribution of multiple myeloma in the United States by sex, age, and race/ethnicity. Blood (2015) 0.77
Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Exp Hematol (2013) 0.77
Autologous stem cell transplantation in elderly patients with multiple myeloma: past, present, and future. Biomed Res Int (2014) 0.77
Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates. Cancer J (2009) 0.77
Pomalidomide for the treatment of multiple myeloma. J Adv Pract Oncol (2014) 0.76
Panobinostat for the treatment of multiple myeloma: the evidence to date. J Blood Med (2015) 0.76
Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma. Clin Med Insights Oncol (2011) 0.76
Innovations in treatment and response evaluation in multiple myeloma. Haematologica (2016) 0.76
Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Chin Med J (Engl) (2015) 0.75
Novel treatment paradigm for elderly patients with multiple myeloma. Am J Blood Res (2011) 0.75
Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice. Mol Ther Oncolytics (2016) 0.75
Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma. Br J Haematol (2009) 0.75
Successful use of cyclophosphamide as an add-on therapy for multiple myeloma patients with acquired resistance to bortezomib or lenalidomide. Case Rep Hematol (2013) 0.75
Immunogenic targets for specific immunotherapy in multiple myeloma. Clin Dev Immunol (2012) 0.75
Efficacy of lenalidomide in association with cyclophosphamide and dexamethasone in multiple myeloma patient with bilateral retro-orbital localisation. Ecancermedicalscience (2013) 0.75
Increasing Disadvantages in Cancer Survival in New Zealand Compared to Australia, between 2000-05 and 2006-10. PLoS One (2016) 0.75
Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries. Sci Rep (2016) 0.75
The impact of hyperglycemia on risk of severe infections during early period of induction therapy in patients with newly diagnosed multiple myeloma. Biomed Res Int (2014) 0.75
Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilities. Oncol Rev (2012) 0.75
Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation. Leuk Suppl (2013) 0.75
Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk (2012) 0.75
Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004. J Natl Cancer Inst (2008) 2.56
Socioeconomic deprivation and cancer survival in Germany: an ecological analysis in 200 districts in Germany. Int J Cancer (2013) 2.18
Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood (2008) 1.65
Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood (2008) 1.65
Recent major progress in long-term cancer patient survival disclosed by modeled period analysis. J Clin Oncol (2007) 1.49
Long-term survival of patients diagnosed with non-Hodgkin lymphoma after a previous malignancy. Leuk Lymphoma (2009) 1.46
Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist (2011) 1.45
Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica (2009) 1.39
Cancer survival differences between European countries and an urban population from the Philippines. Eur J Public Health (2010) 1.38
Clinical relevance of conditional survival of cancer patients in europe: age-specific analyses of 13 cancers. J Clin Oncol (2010) 1.34
Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica (2008) 1.31
Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica (2008) 1.28
The role of HIV-related knowledge and ethnicity in determining HIV risk perception and willingness to undergo HIV testing among rural women in Burkina Faso. AIDS Behav (2005) 1.16
Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981-2005. Cancer (2009) 1.14
Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med (2008) 1.08
Sex differences in colorectal cancer survival: population-based analysis of 164,996 colorectal cancer patients in Germany. PLoS One (2013) 1.05
Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood (2007) 0.99
Subsite-specific colorectal cancer risk in the colorectal endoscopy era. Gastrointest Endosc (2012) 0.98
Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. Oncologist (2011) 0.98
Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century. J Hematol Oncol (2013) 0.96
Survival of cervical cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage. Acta Oncol (2012) 0.90
Cancer survival in Eastern and Western Germany after the fall of the iron curtain. Eur J Epidemiol (2012) 0.89
Survival of stomach and esophagus cancer patients in Germany in the early 21st century. Acta Oncol (2012) 0.88
Inter-country and ethnic variation in colorectal cancer survival: comparisons between a Philippine population, Filipino-Americans and Caucasians. BMC Cancer (2010) 0.86
Improving relative survival, but large remaining differences in survival for non-Hodgkin's lymphoma across Europe and the United States from 1990 to 2004. J Clin Oncol (2010) 0.86
Recent Trends in Survival of Patients With Pancreatic Cancer in Germany and the United States. Pancreas (2016) 0.85
Survival of patients with oral cavity cancer in Germany. PLoS One (2013) 0.85
Survival of endometrial cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage. BMC Cancer (2012) 0.83
Expected long-term survival of older patients diagnosed with non-Hodgkin lymphoma in 2008-2012. Cancer Epidemiol (2011) 0.82
Cancer survival in Lithuania after the restoration of independence: rapid improvements, but persisting major gaps. Acta Oncol (2014) 0.82
Recent cancer survival in Germany: an analysis of common and less common cancers. Int J Cancer (2014) 0.82
Up-to-date estimates of breast cancer survival for the years 2000-2004 in 11 European countries: the role of screening and a comparison with data from the United States. Eur J Cancer (2010) 0.81
Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century. Leuk Lymphoma (2012) 0.80
Inhibition of JNK signaling diminishes early but not late cellular stress-induced apoptosis. Int J Cancer (2003) 0.80
Ethnicity and health care in cervical cancer survival: comparisons between a Filipino resident population, Filipino-Americans, and Caucasians. Cancer Epidemiol Biomarkers Prev (2009) 0.80
Survival of ovarian cancer patients in Germany in the early 21st century: a period analysis by age, histology, laterality, and stage. Eur J Cancer Prev (2013) 0.79
Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. Br J Haematol (2014) 0.79
Survival expectations of patients diagnosed with Hodgkin's lymphoma in 2006-2010. Oncologist (2009) 0.79
Period versus cohort modeling of up-to-date cancer survival. Int J Cancer (2008) 0.78
Ovarian cancer survival population differences: a "high resolution study" comparing Philippine residents, and Filipino-Americans and Caucasians living in the US. BMC Cancer (2009) 0.78
Long-term survival in chronic myelocytic leukemia after a first primary malignancy. Leuk Res (2009) 0.78
Testicular cancer survival in Estonia: improving but still relatively low. Acta Oncol (2010) 0.77
Role of intergenic human gamma-delta-globin sequences in human hemoglobin switching and reactivation of fetal hemoglobin in adult erythroid cells. Ann N Y Acad Sci (2005) 0.77
Minimally Invasive Colorectal Cancer Surgery in Europe: Implementation and Outcomes. Medicine (Baltimore) (2016) 0.75
Breast cancer survival in different country settings: comparisons between a Filipino resident population, Filipino-Americans and Caucasians. Breast (2010) 0.75